10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-Complement C5 Reference Antibody (ravulizumab)

Recombinant Antibody
Catalog # APR10082

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P01031
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG2
Calculated MW	188305

Additional Information

Target/Specificity	Complement C5
Endotoxin Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Protein Information

Name	C5 {ECO:0000303|PubMed:1984448, ECO:0000312|HGNC:HGNC:1331}
Function	Precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:6554279). Activated downstream of classical, alternative, lectin and GZMK complement pathways (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:39914456, PubMed:39814882, PubMed:6554279).
Cellular Location	Secreted. [C5a anaphylatoxin]: Secreted

Images

Anti-Complement C5 Reference Antibody (ravulizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.





The purity of Anti-Complement C5 Reference Antibody (ravulizumab) is 95.57%, determined by SEC-HPLC.



Immobilized Human Complement C5 Protein at 2 μg/mL can bind ravulizumab, EC50=0.1155 μg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.